DRDO-Developed Technology Behind Critical Drug Approved By DCGI For Radiological And Nuclear Emergencies

The Defence Ministry on Tuesday (12 announced that Prussian blue insoluble formulations, a critical drug developed under the Technology Development Fund for radiological and nuclear emergencies, has been granted approval by the Drugs Controller General of India (DCGI).

The drug has been developed by the industry based on the technology of the Institute of Nuclear Medicine & Allied Sciences (INMAS), Delhi, a laboratory of the Defense Research & Development Organisation (DRDO).

Scott-Edil Pharmacia Ltd, Baddi, Himachal Pradesh and Skanttr Lifescience LLP, Ahmedabad, Gujarat have been granted the licenses for manufacturing and marketing the drug for commercial use.

The drug will be available under the trade name of Pru-DecorpTM and PruDecorp-MG.

The formulations are used for decontamination of Cesium and Thallium and its Active Pharmaceutical Ingredient (API), the Defence Ministry said in a statement.

The drug is a critical medicine listed by the World Health Organization (WHO) for radiological and nuclear emergencies.

Samir V Kamat, secretary department of defence R&D and DRDO chairman, has congratulated the Organisation as well as the industry on this achievement.

He stated that the development of these drug formulations under the TDF project and the approval of DCGI is a successful endeavour of the DRDO for promoting the industry to achieve Prime Minister Narendra Modi’s vision of ‘Aatmanirbhar Bharat’.